Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was CNY 18,214.99 million compared to CNY 12,758.04 million a year ago. Net income was CNY 147.3 million compared to CNY 224.51 million a year ago. Basic earnings per share from continuing operations was CNY 0.03 compared to CNY 0.0454 a year ago. Diluted earnings per share from continuing operations was CNY 0.03 compared to CNY 0.0454 a year ago.